Today: 22 January 2026
Subscribe
Browse Category

NASDAQ:GMAB News 18 January 2026 - 19 January 2026

AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

New York, January 19, 2026, 11:19 EST — Market closed. AbbVie Inc shares ended Friday at $214.35, slipping $2.44, or roughly 1.1%. This drop came after AbbVie and partner Genmab announced their blood cancer drug epcoritamab did not demonstrate a clear overall-survival benefit in a late-stage trial. (Reuters) U.S. markets were closed Monday for Martin Luther King Jr. Day, giving…
19 January 2026
······
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

New York, Jan 18, 2026, 11:03 EST — Market closed AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two…
18 January 2026
·······

Stock Market Today

  • Four Seasons Education (NYSE:FEDU) Shares Tumble 30% Amid Mixed Growth Signals
    January 22, 2026, 6:48 AM EST. Shares of Four Seasons Education (Cayman) Inc. (NYSE:FEDU) have plunged 30% in the past month, continuing a difficult 27% decline over the last year. Despite a seemingly attractive price-to-earnings (P/E) ratio of 13.5x, below the U.S. market average of roughly 20x, the company's uneven earnings growth raises concerns. After a striking 323% earnings per share increase last year, the firm showed no growth across the past three years, suggesting inconsistent performance. This lag behind the broader market's projected 16% expansion likely explains the low P/E and wary investor sentiment. The sharp stock drop reflects caution about the company's future growth prospects, signaling that its current valuation more so captures investor apprehension than undervaluation.
Go toTop